Latest Breaking News On - Vascular research - Page 13 : comparemela.com

Better Therapeutics (BTTX) Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001

Better Therapeutics (BTTX) Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMarc bonacaUniversity of coloradoVascular researchDrug administrationBetter therapeutics inc

Meharry names new graduate studies dean

Dr. Merry Lindsey researches cardiovascular system, works with VA

United statesJames hildrethDepartment of cellularUniversity of nebraska medical centerVascular researchMeharry medical collegeSchool of graduateUnited states department of veterans affairsMerry lindseyGraduate studiesUnited states departmentVeterans affairsIntegrative physiologyNebraska medicalMeharry medicalUniversity of nebraska medical center

Better Therapeutics to Participate in Cowen s Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022

SAN FRANCISCO (BUSINESS WIRE) Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value o.

United statesPrapti mehtaMarc bonacaCharles rhyeeMark bermanMark heinenVascular research at colorado prevention centerBetter therapeutics incBetter therapeuticsDigital prescription therapeuticsChief medical officerChief behavioral scientistVascular researchColorado prevention centerColorado schoolBetter therapeutic

Study finds no difference in survival between patients treated with paclitaxel drug-coated devices and non-DCDs

New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.

United statesEric secemskyEmily hendersonSociety for cardiovascular angiography interventionsVascular researchOutcomes research in cardiologySusanf smith centerProfessor of medicine at harvard medical schoolFood drug administrationSafety assessmentFemoropopliteal endovascular treatment withCardiovascular angiographyDrug administrationVascular interventionBeth israel deaconess medical centerSection head

New Longterm Data of Paclitaxel Devices Continues to Show No Increased Mortality Compared to Non-drug Coated Devices

Data Extending through Six Years from the SAFE-PAD Study Presented as Late-Breaking Clinical Research

United statesEric secemskySociety for cardiovascular angiography interventionsVascular researchOutcomes research in cardiologySusanf smith centerProfessor of medicine at harvard medical schoolFood drug administrationSafety assessmentFemoropopliteal endovascular treatment withCardiovascular angiographyDrug administrationVascular interventionBeth israel deaconess medical centerSection headInterventional cardiology